CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,545 enrolled
Drug / intervention
everolimus +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01120249
NCT01120249Phase 3Completed
CompareCT.gov

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

SWOG Cancer Research Network·interventional·Posted May 10, 2010·Updated Sep 16, 2025

In Brief

A Phase 3 clinical trial evaluating everolimus and placebo for Kidney Cancer. Completed, enrolled 1,545 participants across 1,003 sites in 2 countries.

Detailed Summary

RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase III trial is studying everolimus to see how well it works in treating patients with kidney cancer who have undergone surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer
CountriesPuerto Rico, United States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 10, 2010
Enrollment StartApr 1, 2011
Primary CompletionJul 1, 2023
Study CompletionSep 1, 2025
TodayJul 2, 2026
Enrollment to primary: 12.3 yearsPosted 16.1 years ago

Interventions

everolimusdrug

Given orally

placeboother

Given orally